Chalffy/E+ via Getty Images GSK Advances Asthma Care with Innovative Depemokimab Therapy My last article on GSK plc (NYSE:GSK) highlighted their venture into the RSV treatment landscape with Arexvy, the first approved RSV vaccine for older adults. Arexvy inspired a robust Q3 '23 earnings report. I recommended a buy on GSK, and its stock has risen 29.5% versus S&P 500 (SP500) returns of 22.7%. Yesterday, the company revealed late-stage data for their asthma therapy, depemokimab. GSK may have another blockbus ...